REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
REGENXBIO Inc. (RGNX) filed a Current Report on Form 8-K on May 14, 2026. The filing primarily serves to disclose the company's financial results for the quarter ended March 31, 2026, and to announce significant clinical trial data.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the detailed results of operations and financial condition for the quarter ended March 31, 2026. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Clinical Updates
- Clinical Trial Data: On May 14, 2026, the Company presented topline and interim data analysis from the pivotal Phase III AFFINITY DUCHENNE trial of its candidate drug RGX-202.
- Disclosure Method: This clinical data was disclosed under Regulation FD (Item 7.01) and via a separate press release (Item 8.01, Exhibit 99.2).
Guidance, Outlook, and Risks
The filing does not contain explicit forward-looking guidance, management commentary on future financial performance, or a detailed risk factor analysis within the body of the 8-K. The document notes that the information regarding financial results and clinical data is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability under that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 financial metrics including cash position and burn rate.
- Access the "Presentations and Publications" section of the company website or Exhibit 99.2 for the full topline and interim data analysis of the RGX-202 Phase III trial.
- Verify the statistical significance and clinical implications of the AFFINITY DUCHENNE trial results as presented in the May 14, 2026 materials.